Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.
作者信息
Maertens Johan, Slavin Monica, Hoenigl Martin, Thompson George R, Richardson Malcolm, Lass-Flörl Cornelia
机构信息
University Hospitals Leuven, Department of Haematology and ECMM Excellence Center of Medical Mycology, Campus Gasthuisberg Leuven, Belgium.
Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
出版信息
J Antimicrob Chemother. 2024 Aug 1;79(8):1786-1793. doi: 10.1093/jac/dkae158.
Abstract
摘要
相似文献
1
Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.打破常规：挑战侵袭性真菌病临床试验反应定义的现状——一场辩论
J Antimicrob Chemother. 2024 Aug 1;79(8):1786-1793. doi: 10.1093/jac/dkae158.
2
Improving awareness, diagnosis and management of invasive fungal infections in Ghana: establishment of the Ghana Medical Mycology Society.提高加纳侵袭性真菌感染的认识、诊断和管理水平：加纳医学真菌学会的成立。
Med Mycol. 2022 Sep 29;60(9). doi: 10.1093/mmy/myac069.
3
Invasive fungal infections in neonates: a review.新生儿侵袭性真菌感染：综述。
Pediatr Res. 2022 Jan;91(2):404-412. doi: 10.1038/s41390-021-01842-7. Epub 2021 Dec 9.
4
Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.癌症患者侵袭性霉菌感染的诊断和管理的未来挑战和机遇。
Med Mycol. 2021 Jan 4;59(1):93-101. doi: 10.1093/mmy/myaa079.
5
Epidemiology and clinical characteristics of invasive mould infections: A multicenter, retrospective analysis in five Asian countries.侵袭性霉菌感染的流行病学与临床特征：一项在五个亚洲国家开展的多中心回顾性分析
Med Mycol. 2018 Feb 1;56(2):186-196. doi: 10.1093/mmy/myx029.
6
The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections.支持欧洲癌症研究与治疗组织/侵袭性真菌感染协作组（EORTC/MSGERC）修订的侵袭性真菌感染定义的证据。
Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S77-S78. doi: 10.1093/cid/ciaa1765.
7
[Noticeable questions on diagnosis and treatment of invasive fungal infection].[侵袭性真菌感染诊断与治疗中的显著问题]
Zhonghua Nei Ke Za Zhi. 2019 Aug 1;58(8):553-555. doi: 10.3760/cma.j.issn.0578-1426.2019.08.001.
8
Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment.定义成人血液病患者侵袭性真菌病的 CARE 标准：抗真菌预防与治疗。
J Antimicrob Chemother. 2019 Mar 1;74(Suppl 2):ii21-ii26. doi: 10.1093/jac/dkz040.
9
Changes in the epidemiological landscape of invasive mould infections and disease.侵袭性霉菌感染与疾病的流行病学格局变化。
J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i5-i11. doi: 10.1093/jac/dkx028.
10
Executive Summary of Japanese Domestic Guidelines for Management of Deep-seated Mycosis 2014.《2014年日本深部真菌病管理国内指南执行摘要》
Med Mycol J. 2016;57(4):E117-E163. doi: 10.3314/mmj.16-00010.
引用本文的文献
1
Clinical aspects and recent advances in fungal diseases impacting human health.影响人类健康的真菌疾病的临床方面及最新进展。
J Antimicrob Chemother. 2025 Mar 14;80(Supplement_1):i2-i8. doi: 10.1093/jac/dkaf004.
2
Performance of Diagnostic Algorithms in Patients With Invasive Pulmonary Aspergillosis.侵袭性肺曲霉病患者诊断算法的性能
Clin Infect Dis. 2025 Jun 4;80(5):1080-1087. doi: 10.1093/cid/ciae633.
本文引用的文献
1
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris Results from a Phase 2 Trial.新型抗真菌药物 Fosmanogepix 治疗耳念珠菌血症的临床疗效和安全性：一项 2 期临床试验结果
Antimicrob Agents Chemother. 2023 May 17;67(5):e0141922. doi: 10.1128/aac.01419-22. Epub 2023 Apr 6.
2
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study.基于聚合酶链反应的曲霉菌和唑类耐药性检测对侵袭性曲霉菌病的临床影响：一项前瞻性多中心研究。
Clin Infect Dis. 2023 Jul 5;77(1):38-45. doi: 10.1093/cid/ciad141.
3
Invasive Pulmonary Aspergillosis.侵袭性肺曲霉病
J Fungi (Basel). 2023 Jan 17;9(2):131. doi: 10.3390/jof9020131.
4
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM).亚太地区实验室真菌学的现状：来自欧洲医学真菌学联盟（ECMM）和国际人类与动物真菌学会（ISHAM）的调查。
Int J Antimicrob Agents. 2023 Mar;61(3):106718. doi: 10.1016/j.ijantimicag.2023.106718. Epub 2023 Jan 12.
5
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.依布康唑，一种正在研发用于治疗霉菌感染的新型三萜类抗真菌药物。
J Fungi (Basel). 2022 Oct 25;8(11):1121. doi: 10.3390/jof8111121.
6
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update.良好的出版实践（GPP）指南：公司赞助的生物医学研究：2022 更新版。
Ann Intern Med. 2022 Sep;175(9):1298-1304. doi: 10.7326/M22-1460. Epub 2022 Aug 30.
7
The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey.非洲临床真菌学现状：欧洲医学真菌学联合会和国际人类与动物真菌学会调查。
Lancet Microbe. 2022 Jun;3(6):e464-e470. doi: 10.1016/S2666-5247(21)00190-7. Epub 2022 Jan 18.
8
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.侵袭性真菌病的非侵入性检测与替代标志物
Open Forum Infect Dis. 2022 Mar 4;9(6):ofac112. doi: 10.1093/ofid/ofac112. eCollection 2022 Jun.
9
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.抗真菌药物管线上的药物：福沙那韦、依柏西普、奥洛福康唑、泊沙康唑和瑞他康唑。
Drugs. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0. Epub 2021 Oct 9.
10
When to change treatment of acute invasive aspergillosis: an expert viewpoint.何时改变急性侵袭性曲霉病的治疗：专家观点。
J Antimicrob Chemother. 2021 Dec 24;77(1):16-23. doi: 10.1093/jac/dkab317.
Zotero 插件